Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Pharma, Inc.

http://www.astellas.com

Latest From Astellas Pharma, Inc.

Aadi Starts Small With Fyarro, But Has Tumor-Agnostic Strategy In Mind

The approval of Fyarro marks the first for advanced malignant PEComa, a rare cancer that affects only 100-300 people in the US; it's also the first launch for Aadi Biosciences.

Approvals Cancer

Stock Watch: Big Trouble In Small Biotech

While the stock prices of a few biotech companies have advanced significantly as a result of their pandemic efforts, a broad biotech stock index has underperformed the pharmaceutical index. Why?

Stock Watch Coronavirus COVID-19

Janssen’s Sarich: Randomized Controlled Trials, Real-World Evidence Go Best Together

Janssen’s Troy Sarich outlines why it’s hard to emulate randomized controlled trials with real-world evidence studies, emphasizing that the two are “not in competition.” He also highlights the huge strides made by AI-driven technology firms to provide “research-ready” structured data and new game-changing advances in the area of health sensors.

Research & Development Artificial Intelligence

AAV Gene Therapy Panel Shined Light On Safety Issues That Sponsors Have Downplayed – FDA’s Bryan

September advisory committee was less about getting advice and more about calling public attention to AAV gene therapy safety issues, OTAT director Wilson Bryan says. FDA is not ready to set a cap on vector dose but could consider doing so down the road.

Gene Therapy Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced Cell Technology, Inc.
    • Agensys, Inc.
    • Audentes Therapeutics, Inc.
    • Fujisawa GmbH
    • Ganymed Pharmaceuticals AG GmbH
    • iota Biosciences
    • Mytogen, Inc.
    • Nanna Therapeutics Limited
    • Perseid Therapeutics LLC
    • Potenza Therapeutics Inc.
    • Ocata Therapeutics, Inc.
    • OSI Pharmaceuticals, LLC (Cell Pathways
    • Prosidion)
    • Yamanouchi Pharmaceutical Co., Ltd.
    • Ogeda S.A.
    • Mitobridge, Inc.
    • Mitokyne, Inc.
    • Quethera Limited
    • Universal Cells, Inc.
    • Xyphos Biosciences, Inc.
UsernamePublicRestriction

Register